Incyclix Bio

Incyclix Bio is a next-generation cell cycle control company developing small molecule CDK inhibitors for the treatment of advanced and drug-resistant cancers, committed to advancing precision therapies targeting abnormal proliferation that causes many cancers. The company's lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor, soon to enter clinical trials.